News
-
2 min
iQure Pharma’s iQ-007 Completes Critical Go/No Go Criteria - September Start for MTD & GLP Tox Study
-
2 min
iQure Pharma Awarded Second Patent for iQ-007, Novel Therapy to Treat Pain & Epilepsy
-
2 min
iQure Pharma’s iQ-007 Passes Cardiac Safety Test–Critical Milestone for GLP Toxicology Studies
-
1 min
iQure Pharma’s iQ-007 Achieves Critical Pre-Clinical Milestone
-
1 min
iQure Pharma’s iQ-007 & iQ-008 Compounds Continue to Deliver Promising Results
-
1 min
iQure Pharma Attending JPM Week in San Francisco — January 9-12, 2023
-
1 min
iQ-007 shows no abuse potential in FDA recommended panel of tests
-
1 min
iQure Pharma researchers seek non-opioid alternatives to manage pain
-
2 min
iQure Pharma Selected to Join NYU Stern Endless Frontier Labs (EFL) 2022-2023 Life Sciences Track
-
2 min
iQ-007 Considered as First-in-Class Therapeutic Agent in Prestigious Journal of Medicinal Chemistry
-
2 min
iQure Pharma Secures $600K in Commitments in Early Closing to Research Pain Therapies
